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Mycobacterium tuberculosis, the causative agent of tuberculosis, drives the formation of
granulomas, structures in which both immune cells and the bacterial pathogen cohabit.
The most abundant cells in granulomas are macrophages, which contribute as both cells
with bactericidal activity and as targets for M. tuberculosis infection and proliferation dur-
ing the entire course of infection. The mechanisms and factors involved in the regulation
and control of macrophage microenvironment-specific polarization and plasticity are not
well understood, as some granulomas are able to control bacteria growth and others fail
to do so, permitting bacterial spread. In this issue of the European Journal of Immunology,
Venkatasubramanian et al. [Eur. J. Immunol. 2016. 46: 464–479] show that mice lack-
ing the tissue factor gene in myeloid cells have augmented M. tuberculosis growth and
increased inflammation in the lungs. This suggests that tissue factor, an initiator of coag-
ulation, is important for the generation of fibrin, which supports granuloma formation.
This article demonstrates for the first time the involvement of tissue factor in inducing
effective immunity against M. tuberculosis, and sheds new lights on the complex inter-
play between host inflammatory response, the coagulation system, and the control of
M. tuberculosis infection.
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Tuberculosis (TB) represents a global health problem: according to
the World Health Organization Global Tuberculosis Report 2013,
an estimated 8.6 million people developed TB and 1.3 million died
from the disease in 2012 [1]. The pathogen responsible for this
widespread and persistent infection is Mycobacterium (M.) tuber-
culosis, which resides in macrophages and induces the death of its
host cells. Infection starts when inhaled bacilli are phagocytosed
by alveolar macrophages. Once inside the phagocyte, M. tuber-
culosis regulates the activity of its phagosome by preventing its
Correspondence: Prof. Francesco Dieli
e-mail: francesco.dieli@unipa.it
fusion with acidic, hydrolytically active lysosomes. In experimen-
tal hosts such as mice, this marks the start of a period of rapid divi-
sion in which the bacteria grow exponentially inside macrophages
until the emergence of an acquired immune response. This is con-
comitant with the development of the granuloma, which signifies
immune-mediated containment of the infection. The granuloma
can proceed either to localized sterilization of the infection and
mineralization of the lesion, or to localized caseation and necro-
sis, which culminates in the release of infectious bacteria into the
airways (reviewed in [2–4]).
Macrophages have been classified along the lines of their differ-
ent activation states; M1 macrophages, for example, are polarized
by Toll-like receptor (TLR) ligands and interferon (IFN) γ, while
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M2 macrophages are polarized by interleukin (IL) 4, IL-13, and
IL-10 [4–8]. M1 macrophages are characterized by their expres-
sion of high levels of proinflammatory cytokines (e.g., TNF-α),
high production of reactive nitrogen and oxygen intermediates,
promotion of a Th1 response, and strong microbicidal and tumo-
ricidal activity [5–9]. This type of macrophage is connected to
resistance to infection with intracellular bacteria, and character-
izes the early phases of infection withM. tuberculosis in mice [10].
Conversely, M2 macrophages are characterized by the expression
of anti-inflammatory cytokines (e.g., IL-10) and the promotion of
tissue healing and remodeling, as well as by immunoregulatory
functions [7–9]. In vitro and in vivo experimental studies have
both shown that these polarized macrophage phenotypes can be
reversible [11–15]. It has been reported that a switch between
pro- and anti-inflammatory cytokine profiles can be observed dur-
ing the transition from acute to chronic infection, and that this may
be a mechanism that provides protection against excessive inflam-
mation. On the other hand, the switch in macrophage polarization
toward the M2 phenotype has been shown to be a strategy to inter-
fere with M1-associated killing in experimental tumor [12, 13]
and infection models [16]. Therefore, a better understanding of
macrophage differentiation programs could be useful to develop
strategies to target and manipulate their functions in vivo.
In this issue of the European Journal of Immunology, Venkata-
subramanian et al. [17] report that the expression of tissue fac-
tor (TF, a transmembrane glycoprotein involved in hemostasis by
activating coagulation) in macrophages controls M. tuberculosis
growth and dissemination, providing evidence that this molecule
contributes to an effective immune response against this intra-
cellular pathogen. TF (also known as Factor III, thromboplastin
or CD142) is the principal initiator of the coagulation cascade
(reviewed in [18]). It is a 47 kDa transmembrane glycoprotein
receptor found on the surface of a variety of cells, including
platelets, leukocytes, fibroblasts, and endothelial cells, as well as in
the smooth muscle cells surrounding the vessel walls. TF has been
shown to be expressed in response to injury (such as infections,
inflammation, tumor growth, and atherosclerosis [18]), as well as
to a number of different extracellular stimuli, including LPS, TFN-
α, IL-1, IL-2, IL-6, IFN-γ, lipoprotein, FVIIa, plasmin, angiotensin
II, and hypoxia [18]. TF plays many diverse roles, and in addition
to promoting blood coagulation, it is involved in embryonic devel-
opment, angiogenesis, tumor metastasis, cell adhesion/migration,
inflammation, and innate immunity [18].
TF expression on monocytes and endothelial cells has been
shown to occur during several different bacterial infections in
which TF plays a dual role—on the one side it contributes to
infection-associated mortality and inflammation, as in the case of
Toxoplasma and Listeria infection of mice, while on other side it
plays a protective role by limiting pathogen burden and dissemi-
nation, as in the case of Yersinia and Escherichia coli infection of
mice and rats, respectively [19–22].
A previous study has evaluated the role of TF in the M. tuber-
culosis induced inflammatory response, using transgenic mice that
express either very low or normal levels of human TF [23]. It was
shown that M. tuberculosis infection does not increase TF expres-
sion in the lungs, although the macrophages in the granulomatous
lung lesions showed increased levels of TF expression [21]. How-
ever, there were no significant differences in pro-inflammatory
cytokines among wild-type and TF-transgenic mice and mycobac-
terial burden and dissemination into organs of mice were essen-
tially similar in all tested mice. This indicates that TF does not
contribute to the overall defense against M. tuberculosis challenge
[21].
Venkatasubramanian et al. [17] instead have used mice with
selective inactivation of the TF gene in myeloid cells to study
the role of TF in M. tuberculosis infection. They found that TF
expression by myeloid cells contributes to the protective immune
response against M. tuberculosis. In particular, TF deficiency
in myeloid cells is associated with enhanced IL-10 production,
reduced inducible nitric oxide synthase (iNOS) expression and
enhanced arginase 1 (Arg1) expression, increased MMP-2 and
MMP-9-mediated inflammation, and decreased fibrin deposition
in the lungs during M. tuberculosis infection [17] See Figure 1.
Taken together, these responses are associated with increased M.
tuberculosis replication in the lungs.
One of the hallmark features of TB pathology is the devel-
opment of granulomas, which contain not only the infection but
also the host inflammatory response. Granulomas are aggregates
of organized immune cells consisting of blood-derived cells, such
as giant-multinucleated cells, lymphocytes, and fibroblasts and
finally, at a later stage, they become surrounded by fibrosis, which
has the role of demarcating and containing the infection. The
granuloma has an innate inflammatory basis but Th1 cells play a
key role in its formation and maintenance. According to a recent
review [24], three distinct types of granulomas, each correlat-
ing with a different stage of M. tuberculosis infection, have been
described in humans. Solid granuloma, characterized by low bac-
terial growth and metabolic activity of M. tuberculosis, is charac-
teristic of latent M. tuberculosis infection [24]. In the transition
to active TB disease, solid granulomas develop central necrosis,
together with the transformation ofM. tuberculosis into a metabol-
ically active and highly replicative pathogen [24]. Liquefaction of
the necrotic granuloma leads to the formation of caseous granu-
loma and cavities with tissue damage [24]. In patients with active
TB infection, the three forms of granuloma co-exist, although
necrotic and caseous granulomas predominate [24]. In a work-
ing granuloma, both innate and adaptive immune responses are
organized to contain the infection; however, knowledge on the
specific factors that facilitate the formation of functional granulo-
mas capable of eliminating or containingM. tuberculosis is limited.
Since TF is key element in the generation of fibrin, which in turn
plays an important role in granuloma formation, it is possible
that during M. tuberculosis infection, TF expression on the surface
of activated macrophages may contribute to the containment of
mycobacterial infection through fibrin generation.
Histology data in TF-deficient mice [17] have shown increased
inflammation with elevated numbers of small granulomas con-
taining elevated numbers of IL-10-positive foamyM2macrophages
[17].Whether or not these IL-10-positive foamymacrophages con-
tainM. tuberculosis bacilli and express pro-inflammatory cytokines
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Figure 1. TF is expressed in response to injury
(left), as well as to a number of different
extracellular stimuli, including LPS, TNF-α, IL-
1, IL-2, IL-6, IFN-γ, lipoprotein, FVIIa, plas-
min, angiotensin II, and hypoxia. TF is an
initiator of the coagulation cascade, and is
involved in fibrin generation and deposition,
which is important in granuloma formation.
TF expression by myeloid cells has also been
shown to contribute to the protective immune
response against M. tuberculosis. In particular,
TF deficiency in myeloid cells (right) is associ-
ated with enhanced IL-10 production, reduced
iNOS expression and enhanced arginase 1
(Arg1) expression, increased MMP-2- and MMP-
9-mediated inflammation and decreased fibrin
deposition in lungs. Overall, this drives inflam-
mation and damage, and is ultimately associ-
ated with increased M. tuberculosis replication
(right).
has not been investigated in the study of Venkatasubramania et al.
[17]. Thus, the development of an exaggerated host inflamma-
tory response in the presence of increased levels of IL-10, clearly
indicates that TF deficiency promotes an inappropriate (M2 type)
innate response, supporting the concept that one of the major
roles of the granuloma is to localize and contain not only the bac-
teria but also the inflammatory response to the bacteria itself.
Indeed, if immune cells are not tightly controlled within the
lungs, this could lead to excessive inflammation, as previously
demonstrated by ourselves in mice lacking inhibitory receptors for
pro-inflammatory cytokines (such as Tir8, [25]) and chemokines
(such as D6, [26]). Thus, rigorous control of granuloma orga-
nization is likely necessary to prevent immunopathology. There-
fore, TF may favor resolution of chronic inflammatory responses
and overall provide a fine mechanism for the control of the bal-
ance between protective immune responses and immunopathol-
ogy, possibly inhibiting some signaling pathways to prevent the
polarization toward M2 macrophages during infection. It should
be stressed that TB is a chronic disease, but experiments in this
study were performed at a single time point of 30 days [17], which
reflects the participation of innate immune responses and early
stages of adaptive response to M. tuberculosis, making it impossi-
ble to clearly identify the role of TF in the long-term control of
M. tuberculosis infection and disease.
In conclusion, Venkatasubramanian et al. [17] provide evi-
dence that TF expressed by myeloid cells contributes to protec-
tive immunity against M. tuberculosis infection. This may have
implications for both vaccine and chemotherapy programs. The
progression of TB seems to be determined locally, independently
of the nature of the systemic immune response. Therefore, to be
maximally effective, vaccines need to limit bacterial growth before
granuloma formation, because once formed the granuloma pro-
tects M. tuberculosis and prevents bacterial clearance. The data
also indicate that there might be avenues for manipulating the
host tissue response to infection that could interfere with the tis-
sue state needed to support persistent organisms.
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